Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study

Blood

Volumn 117, Issue 6, 2011, Pages 1834-1839

  Jaccard, Arnaud ^a   Gachard, Nathalie ^a   Marin, Benoit ^a   Rogez, Sylvie ^a   Audrain, Marie ^b   Suarez, Felipe ^c   Tilly, Hervé ^d   Morschhauser, Franck ^e   Thieblemont, Catherine ^f   Ysebaert, Loic ^g   Devidas, Alain ^h   Petit, Barbara ^a   De Leval, Laurence ⁱ   Gaulard, Philippe ^j   Feuillard, Jean ^a   Bordessoule, Dominique ^a   Hermine, Olivier ^c  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d CENTRE HENRI BECQUEREL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g CHU PURPAN   (France)

^h CENTRE HOSPITALIER SUD FRANCILIEN   (France)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ASPARAGINASE; ASPARAGINASE ANTIBODY; CARMUSTINE; CYTARABINE; DEXAMETHASONE; ERWINIASE; ETOPOSIDE; MELPHALAN; METHOTREXATE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NK T CELL LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; THROMBOCYTOPENIA; THROMBOSIS;

EID: 79951483189     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-307454     Document Type: Article

References (34)

1. Emile JF, Boulland ML, Haioun C, et al. CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood. 1996;87(4):1466-1473. (Pubitemid 26056911)
2. Kluin PM, Feller A, Gaulard P, et al. Peripheral T/NK-cell lymphoma: a report of the IXth Workshop of the European Association for Haematopathology. Histopathology. 2001;38(3):250-270. (Pubitemid 32862736)
3. Jaffe ES, Lee Harris N, Stein H, Vardiman JW. Tumors of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2001.
4. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139(4):532-544. (Pubitemid 350043813)
5. Kwong YL, Anderson BO, Advani R, et al. Management of T-cell and natural-killer-cell neoplasms in Asia: Consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10(11):1093-1101.
6. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T cell lymphoma. J Clin Oncol. 2006;24(1): 181-189. (Pubitemid 46630511)
7. Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006;106(3):609-615. (Pubitemid 43157624)
8. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009;27(35):6027-6032.
9. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76(11):2351- 1256.
10. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216-221.
11. Kim BS, Kim DW, Im SA, et al. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol. 2009;20(1):121-128.
12. Jaccard A, Petit B, Girault S, et al. L-Asparaginase-based treatment of 15 Western patients with extranodal NK/T-cell lymphoma and leukaemia and a review of the literature. An Oncol. 2009;20(1): 110-116.
13. Yong W, Zheng W, Zhang Y. Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma. Zhonghua Yi Xue Za Zhi. 2001;81(13):773-775.
14. YongW, ZhengW, Zhang Y, et al. L-Asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003;78(2):163-167. (Pubitemid 37021959)
15. Yong W, Zheng W, Zhu J, et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol. 2006;24(1): 28-32.
16. Yong W, Zheng W, Zhu J, et al. L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2009;88(7):647-652.
17. Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol. 2005;130(6):860-868. (Pubitemid 43899727)
18. Nowak-Gottl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003;101(7):2529-2533. (Pubitemid 36857608)
19. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1): 243-249. (Pubitemid 38879864)
20. Wang B, Hak LJ, Relling MV, Pui CH, Woo MH, Storm MC. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods. 2000;239(1):75-83. (Pubitemid 30256020)
21. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
22. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982; 38(1):143-151.
23. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal NK/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2009;113(17):3931-3937
24. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19(12): 2186-2194.
25. Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol. 2003;40(3):221-232. (Pubitemid 36842600)
26. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase 1 study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99(5): 1016-1020. (Pubitemid 351997606)
27. Nagafuji K, Fujisaki T, Arima F, Ohshima K. L-Asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol. 2001;74(4):447-450. (Pubitemid 33760107)
28. Obama K, Tara M, Niina K. L-Asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol. 2003;78(3): 248-250. (Pubitemid 37288512)
29. Matsumoto Y, Nomura K, Kanda-Akano, et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma. 2003;44(5):879-882. (Pubitemid 36410998)
30. Hyakuna N, Toguchi S, Higa T, et al. Childhood blastic NK cell leukaemia successfully treated with L-asparaginase and allogeneic bone marrow transplantation. Pediatr Blood Cancer. 2004;42(7):631-634. (Pubitemid 38669752)
31. Sakamoto E, Yamane T, Nakane T, et al. Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK/T-cell lymphoma. Gan To Kagaku Ryoho. 2005;32(12):1993-1996.
32. Yokoyama H, Yamada MF, Ishizawa K, et al. Successful treatment of advanced extranodal NK/T cell lymphoma with unrelated cord blood transplantation. Tohoku J Exp Med. 2007;211(4):395-399. (Pubitemid 46585553)
33. Reyes VE Jr, Al-Saleem T, Robu VG, Smith MR. Extranodal NK/T-cell lymphoma nasal type: efficacy of pegaspargase. Report of two patients from the United Sates and review of literature. Leuk Res. 2010;34(1):e50-e54.
34. Zalewska-Szewczyk B, Andrzejewski W, Çynarski W, Jedrychowska-Da Ñska K, Witas H, Bodalski J. The anti-asparagine antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2007;48(5):931-936. (Pubitemid 47161565)